Disclosures for "Anti-JC Virus Serostatus Changes Before and During the COVID-19 Pandemic in US Patients with Multiple Sclerosis (MS) Treated with Natalizumab")
-
Dr. Krieger has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Krieger has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for EMD Serono. Dr. Krieger has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech. Dr. Krieger has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Krieger has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for TG Therapeutics. Dr. Krieger has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Krieger has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Expert Witness. The institution of Dr. Krieger has received research support from Novartis. The institution of Dr. Krieger has received research support from Bristol Myers Squibb.
-
Mrs. Sinks has received personal compensation for serving as an employee of Biogen .
-
Dr. Huang has nothing to disclose.
-
Ms. Wen has a non-compensated relationship as a Statistician with Biogen that is relevant to AAN interests or activities.
-
Mrs. Steverson has received personal compensation for serving as an employee of Biogen. Mrs. Steverson has stock in Biogen.
-
An immediate family member of Dr. Piccinini has received personal compensation for serving as an employee of Biogen. Dr. Piccinini has received stock or an ownership interest from Biogen.
-
Dr. Kalina has received personal compensation for serving as an employee of Biogen.
-
Dr. White has stock in Biogen.
-
Mrs. Avila has received personal compensation for serving as an employee of Biogen. Mrs. Avila has stock in Biogen.